Literature DB >> 12537681

In vivo transscleral iontophoresis of amikacin to rabbit eyes.

David L Vollmer1, Margaret A Szlek, Kenneth Kolb, Lindsay B Lloyd, Thomas M Parkinson.   

Abstract

The objectives of these studies were to determine the amount and distribution of the aminoglycoside antibiotic amikacin delivered to rabbit eyes following transscleral iontophoresis and to determine the inter-study reproducibility of delivery over three identical studies. New Zealand White rabbits (N = 6 per dose group) were treated with a 200-mg/mL amikacin solution at 0, 2, 3 or 4 mA of (+) DC current for 20 minutes. Amikacin concentrations in eye tissues were highest with the 4-mA treatment. Concentrations for all three studies at this current were approximately 5.4, 40, 41, 343, and 92 mcg/g in the vitreous humor, anterior segment, non-treated hemisphere of the sclera, treated hemisphere of the sclera, and retina/choroid, respectively. These values were approximately 27, 50, 40, 10, and 13 fold greater than in the 0-mA control group and are well above the in vitro minimum inhibitory concentrations (MICs) for this drug. Inter-study reproducibility (measured as %CV) depended on the tissue type and treatment group and ranged from 8% for the retina/choroid to 51% for the anterior segment in the 4-mA group. Pretreatment with topical proparacaine hydrochloride local anesthetic did not affect amikacin delivery and total drug delivered was not affected by delivery time for the same total charge administered. Therapeutically relevant amounts of amikacin were delivered into eye tissues in a reproducible and controllable manner.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12537681     DOI: 10.1089/108076802321021090

Source DB:  PubMed          Journal:  J Ocul Pharmacol Ther        ISSN: 1080-7683            Impact factor:   2.671


  8 in total

1.  Computer modeling of drug delivery to the posterior eye: effect of active transport and loss to choroidal blood flow.

Authors:  Ram K Balachandran; Victor H Barocas
Journal:  Pharm Res       Date:  2008-08-05       Impact factor: 4.200

Review 2.  New techniques for drug delivery to the posterior eye segment.

Authors:  Esther Eljarrat-Binstock; Jacob Pe'er; Abraham J Domb
Journal:  Pharm Res       Date:  2010-02-13       Impact factor: 4.200

3.  Ocular drug delivery targeted by iontophoresis in the suprachoroidal space using a microneedle.

Authors:  Jae Hwan Jung; Bryce Chiang; Hans E Grossniklaus; Mark R Prausnitz
Journal:  J Control Release       Date:  2018-03-02       Impact factor: 9.776

4.  Examination of penetration routes and distribution of ionic permeants during and after transscleral iontophoresis with magnetic resonance imaging.

Authors:  Sarah A Molokhia; Eun-Kee Jeong; William I Higuchi; S Kevin Li
Journal:  Int J Pharm       Date:  2006-11-03       Impact factor: 5.875

5.  A Hydrogel Ionic Circuit Based High-Intensity Iontophoresis Device for Intraocular Macromolecule and Nanoparticle Delivery.

Authors:  Fan Zhao; Shan Fan; Deepta Ghate; Svetlana Romanova; Tatiana K Bronich; Siwei Zhao
Journal:  Adv Mater       Date:  2021-12-08       Impact factor: 30.849

Review 6.  Recent perspectives in ocular drug delivery.

Authors:  Ripal Gaudana; J Jwala; Sai H S Boddu; Ashim K Mitra
Journal:  Pharm Res       Date:  2008-08-29       Impact factor: 4.200

7.  Transscleral iontophoretic and intravitreal delivery of a macromolecule: study of ocular distribution in vivo and postmortem with MRI.

Authors:  Sarah A Molokhia; Eun-Kee Jeong; William I Higuchi; S Kevin Li
Journal:  Exp Eye Res       Date:  2008-11-01       Impact factor: 3.467

Review 8.  Selected Medicines Used in Iontophoresis.

Authors:  Tomasz M Karpiński
Journal:  Pharmaceutics       Date:  2018-10-25       Impact factor: 6.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.